The short version of AOD9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-11. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Valve, the developers of Source and Half-Life 2, contacted Newman to suggest a commercial, standalone release of the mod through their digital distribution service Steam, which Newman initially rejected. Valve and Facepunch later struck a publishing agreement wherein Valve would release Garry's Mod onto Steam at a price of US$10, while the two companies would equally split profits. The last free version of Garry's Mod remained available for download, rechristened as the demo to the retail game. The standalone game was released on 29 November 2006. Despite the game no longer being a mod, Valve and Facepunch stuck with the "Garry's Mod" name, which Newman later cited as a mistake, stating that he should have called it "Sandbox" instead. Because Garry's Mod still required a separate Source-based game to function properly, a bundle including Garry's Mod and Valve's Counter-Strike: Source was released alongside. A port of the Windows version for Mac OS X was released on 23 September 2010. Support for Kinect, a full-body motion tracking peripheral, was added to the Windows version in December 2012. When Garry's Mod was moved over to Valve's SteamPipe content delivery system, completed on 5 June 2013, an experimental Linux client was also introduced. In 2025, an update to the game added popularly-used assets from Counter-Strike: Source and episodic content from Half-Life 2, addressing a majority of missing content issues found in community maps and caused by not having the aforementioned games installed.
The dimerization reaction is unselective. By-products include acetaldehyde (due to isomerization). The selectivity and speed of dimerization can be increased by adding a catalyst, such as platinum, platinum-palladium, or iodine with sulfolane. 2-methyl-1,3-dioxolane is formed as a side product in the last case.
In humans, 24 copies of E2 arranged in octahedral symmetry form the core of the BCKDC. Non-covalently linked to this polymer of 24 E2 subunits are 12 E1 α2β2 tetramers and 6 E3 homodimers. In addition to the E1/E3-binding domain, there are 2 other important structural domains in the E2 subunit: (i) a lipoyl-bearing domain in the amino-terminal portion of the protein and (ii) an inner-core domain in the carboxy-terminal portion. The inner-core domain is linked to the other two domains of the E2 subunit by two interdomain segments (linkers). The inner-core domain is necessary to form the oligomeric core of the enzyme complex and catalyzes the acyltransferase reaction (shown in the "Mechanism" section below). The lipoyl domain of E2 is free to swing between the active sites of the E1, E2, and E3 subunits on the assembled BCKDC by virtue of the conformational flexibility of the aforementioned linkers (see Figure 2). Thus, in terms of function as well as structure, the E2 component plays a central role in the overall reaction catalyzed by the BCKDC.
== Applications == Chemical crosslinking of intracellular proteins prior to cell lysis and immunoprecipitation 'Fix' protein interactions to allow identification of weak or transient protein interactions Protein crosslinking to create bioconjugates via single-step reactions Immobilize proteins onto amine-coated surfaces Crosslinking mass spectrometry (crosslinking-MS) provides insight into protein structure, organization, and interactions
Relaxin is a protein hormone of about 6000 Da, first described in 1926 by Frederick Hisaw. The relaxin family peptide hormones belong to the insulin superfamily and consists of seven peptides of high structural but low sequence similarity; relaxin-1 (RLN1), 2 (RLN2) and 3 (RLN3), and the insulin-like (INSL) peptides, INSL3, INSL4, INSL5 and INSL6. The functions of relaxin-3, INSL4, INSL5, and INSL6 remain uncharacterised.
Sources: en.wikipedia.org
That said, Jung's concept of individuation—that is the integration of the archaic unconscious with consciousness—seems extremely pertinent to modern psychedelic research." The author also uses work in evolutionary and psychedelic neuroscience, and specifically the latter's ability to make manifest ancient subcortical brain systems, to illuminate Jung's concept of an archaic collective unconscious that evolved before the ego complex and the uniquely human default mode network.
If the branched and complex structures seen in cpDNA experiments are real and not artifacts of concatenated circular DNA or broken circles, then a D-loop mechanism of replication is insufficient to explain how those structures would replicate. At the same time, homologous recombination does not expand the multiple A --> G gradients seen in plastomes. Because of the failure to explain the deamination gradient as well as the numerous plant species that have been shown to have circular cpDNA, the predominant theory continues to hold that most cpDNA is circular and most likely replicates via a D loop mechanism.
=== Valorization and circular economy === Recent trends in the dairy industry focus on a circular economy approach, transforming whey treatment plants into biorefineries. Instead of producing only biogas, processes can be tuned for acidogenic fermentation to produce volatile fatty acids (VFAs) via the carboxylate platform. Recent findings suggest that applying thermal and alkaline pre-treatments to the inoculum can effectively halt methanogenesis, thereby favoring the accumulation of VFAs, which serve as valuable precursors for bioplastics and other chemicals. Integrated systems coupling anaerobic digestion with microalgae cultivation have also been proposed. In these "closed-loop" scenarios, the nutrient-rich digestate serves as a substrate for microalgal biomass production, which can be harvested for biofuels or high-value pigments, while simultaneously recovering nitrogen and phosphorus (e.g., as struvite).
Rauvolfia serpentina, the Indian snakeroot, devil pepper, serpentine wood, Sarpagandha (as known locally) or Chandrika, is a species of flower in the milkweed family Apocynaceae. It is native to the Indian subcontinent and East Asia (from India to Indonesia). Rauvolfia is a perennial undershrub widely distributed in India in the sub-Himalayan regions up to 1,000 metres (3,300 ft). Sarpagandha is used in folk medicine in India for centuries to treat a wide variety of maladies, including snake and insect bites, febrile conditions, malaria, abdominal pain, and dysentery. It was also used as a uterine stimulant, febrifuge, and cure for insanity. The plant was mentioned in Hindu manuscripts as long ago as 1000 BCE.
== Structure == Sucrose is a disaccharide formed from condensation of glucose and fructose to produce α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside. Sucrose has 8 hydroxyl groups which can be reacted with fatty acid esters to produce sucrose esters. Among the 8 hydroxyl groups on sucrose, three (C6, C1', and C6') are primary while the others (C2, C3, C4, C3', and C4') are secondary. (The numbers 1-6 indicate the position of the carbons on glucose while the numbers 1'-6' indicate the position of the carbons on fructose.) The three primary hydroxyl groups are more reactive due to lower steric hindrance, so they react with fatty acids first, resulting in a sucrose mono-, di-, or triester. Typical saturated fatty acids that are used to produce sucrose esters are lauric acid, myristic acid, palmitic acid, stearic acid and behenic acid, and typical unsaturated fatty acids are oleic acid and erucic acid.
Sources: en.wikipedia.org
Methane clumped isotopes are methane molecules that contain two or more rare isotopes. Methane (CH4) contains two elements, carbon and hydrogen, each of which has two stable isotopes. For carbon, 98.9% are in the form of carbon-12 (12C) and 1.1% are carbon-13 (13C); while for hydrogen, 99.99% are in the form of protium (1H) and 0.01% are deuterium (2H or D). Carbon-13 (13C) and deuterium (2H or D) are rare isotopes in methane molecules. The abundance of the clumped isotopes provides information independent from the traditional carbon or hydrogen isotope composition of methane molecules.
=== Progestogenic activity === CPA is a highly potent progestogen. It is described as the most potent progestin of the 17α-hydroxyprogesterone group, being about 1,200-fold more potent than hydroxyprogesterone acetate, 12-fold more potent than medroxyprogesterone acetate, and 3-fold more potent than chlormadinone acetate in animal bioassays. Based on results in the animal bioassays, CPA has also been said to be the most potent progestin known, with 1,000 times the potency of progesterone. With oral administration in humans however, CPA is distinctly less potent as a progestogen than various other progestins such as the 19-nortestosterone derivatives. The effective dosage of CPA needed to inhibit ovulation by itself in women (i.e., to act as a contraceptive) is 1 mg/day, and the medication is marketed as a contraceptive (combined with low-dose ethinylestradiol) at a dosage of 2 mg/day. For comparison, the ovulation-inhibiting dosage of levonorgestrel is 50 μg/day. At the dosages typically used clinically, CPA is described as a "strong" and "powerful" progestogen. Its endometrial transformation dosage is 20 to 30 mg per cycle and its menstrual delay test dosage has been estimated to be less than 1 mg/day. CPA is not well-balanced in terms of its activities; relative to the progestogenic potency of CPA, its potency as an androgen receptor antagonist is quite weak. In order to take full advantage of its antiandrogenic activity, CPA must be administered at a dosage of 50 to 100 mg per day, which is 2 to 3 times the cyclical endometrial transformation dose per day.
The New Zealand Defence Force proposes disestablishing 697 civilian roles as part of a restructuring process. 23 March: Hundreds of protesters gather outside the New Zealand Parliament to protest against the Government's plans to review the prescription of puberty blockers in "gender affirming care." New Zealand First leader and Deputy Prime Minister Winston Peters delivers a state of the nation speech at the James Hay Theatre in Christchurch, focusing on alleged wokeism and DEI issues. The event is picketed by both pro and anti-greyhound racing, pro-Palestinian and pro-Israel protesters. Police arrest 10 individuals for disrupting the event. 25 March: The High Court rejects the Whangārei District Council's bid to challenge the Director-General of Health's order to fluoridate its water supply. A magnitude 6.8 earthquake hits off the coast of Southland, producing a 10 cm (3.9 in)-tsunami. Cracks in the Dunedin Gasworks Museum were later found and may have been caused by the earthquake. The Tararua District Council issues a boil water notice in Woodville after rodent feces were found in the rafters of the town's reservoir building. 26 March: Queenstown residents protest against a decision by the Queenstown Lakes District Council to discharge treated sewage into the Shotover River. Mental Health Minister Matt Doocey acknowledges that Police accidentally sent an 11-year old autistic girl to a mental institution following a case of mistaken identity. The girl received at least two doses of anti-psychotic medicine.
== Other == Civic Democratic Party (Czech: Občanská demokratická strana) Civic Democratic Party (Slovakia) (Slovak: Občianska demokratická strana) Odesa International Airport, an airport in Odesa, Ukraine (IATA code ODS) L'Officiel du jeu Scrabble, the reference dictionary for Scrabble in French-speaking countries One Day School, a gifted education program in New Zealand. Operating Deflection Shape, a method used for visualisation of the vibration pattern of a machine Ordbog over det danske Sprog, a dictionary of Danish Overdoses (especially drug overdoses) In Liverpool in England, Old Dock Sill Orbital Dysfunctional Syndrome from the film Pandorum Occupy Dame Street, a protest in Dublin, Ireland in 2011–12
== External links == 16S rRNA, BioMineWiki Archived 2019-04-27 at the Wayback Machine Ribosomal Database Project II Archived 2020-08-19 at the Wayback Machine Ribosomal+RNA at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SILVA rRNA Database Project (also includes Eukaryotes (18S) and LSU (23S/28S)) Video: rRNA: sequence, function & synthesis Halococcus morrhuae (archaebacterium) 5S rRNA
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.